Matteo Serenelli
Overview
Explore the profile of Matteo Serenelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Serenelli M, Dal Passo B, Biscaglia S, Tolomeo P, Di Ienno L, Cantone A, et al.
Open Heart
. 2024 Mar;
11(1).
PMID: 38485286
Background: The diagnosis of myocardial infarction (MI) in the presence of heart failure (HF) presents a clinical problem. While diagnostic algorithms using high-sensitivity cardiac troponin have been established for suspected...
12.
Pavasini R, Campo G, Serenelli M, Tonet E, Guiducci V, Escaned J, et al.
Eur J Prev Cardiol
. 2024 Mar;
31(12):1451-1459.
PMID: 38452238
Aims: The present analysis from the Functional Assessment in Elderly Myocardial Infarction Patients with Multivessel Disease (FIRE) trial aims to explore the significance of pre-admission physical activity and assess whether...
13.
Frascaro F, Bianchi N, Sanguettoli F, Marchini F, Meossi S, Zanarelli L, et al.
J Clin Med
. 2023 Dec;
12(24).
PMID: 38137806
Immune checkpoint molecules like cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), play a critical role in regulating the...
14.
Aimo A, Teresi L, Castiglione V, Picerni A, Niccolai M, Severino S, et al.
Amyloid
. 2023 Sep;
31(1):52-61.
PMID: 37668548
Background: Transthyretin cardiac amyloidosis (ATTR-CA) has a deep impact on the quality of life (QoL), yet no specific patient-reported outcome measures (PROMs) for ATTR-CA exist. Methods: The ITALY study involved...
15.
Cantone A, Serenelli M, Sanguettoli F, Maio D, Fabbri G, Dal Passo B, et al.
ESC Heart Fail
. 2023 Jun;
10(4):2740-2744.
PMID: 37264762
Background: The clinical value of cardiopulmonary exercise testing (CPET) in cardiac amyloidosis (CA) is uncertain. Due to the growing prevalence of the disease and the current availability of disease-modifying drugs,...
16.
Ferrari R, Cimaglia P, Cantone A, Serenelli M, Guardigli G
Eur Heart J Suppl
. 2023 May;
25(Suppl C):C44-C48.
PMID: 37125296
Cardiovascular disease (CVD) is a chronic condition driven by the complex interaction of different risk factors including genetics, lifestyle, environment, etc. which, differently from other pathologies, can be prevented. Treatment...
17.
Rauf M, Hawkins P, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al.
Eur Heart J
. 2023 Mar;
44(24):2187-2198.
PMID: 36946431
Aims: To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio...
18.
Pavasini R, Sanguettoli F, Deserio M, Bianchi N, Zanarelli L, Fabbri G, et al.
Minerva Cardiol Angiol
. 2023 Mar;
71(6):611-621.
PMID: 36939732
Introduction: Marfan Syndrome (MFS) is a rare and complex genetic disorder associated with increased aortic growth and aortic disease. The effectiveness of cardiovascular medical therapies aiming to slow down aortic...
19.
Tini G, Milani P, Zampieri M, Caponetti A, Fabris F, Foli A, et al.
Eur J Heart Fail
. 2023 Mar;
25(6):845-853.
PMID: 36907828
Aim: Epidemiology of wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) remains poorly defined. A better characterization of pathways leading to ATTRwt-CA diagnosis is of key importance, and potentially informative of disease course...
20.
Serenelli M, Cantone A, Dal Passo B, Di Ienno L, Fiorio A, Pavasini R, et al.
JACC Cardiovasc Imaging
. 2023 Jan;
16(3):392-395.
PMID: 36648050
No abstract available.